| |
| INDUSTRY SYMPOSIA |
| |
| |
• Industry Symposium ROCHE
|
Saturday, July 15 2006 – 16.00-17.30
|
|
Biosimilars in question: complexities and concerns |
|
| Chair: David Goldsmith, London, United Kingdom |
| |
| Welcome |
| |
Biosimilars in question: complexities and concerns |
David Goldsmith, London, United Kingdom |
| |
Biosimilars in the Lab: creating biopharmaceuticals |
Martin Kuhlmann, Berlin, Germany
|
|
Biosimilars in the Clinic: lessons learnt from case histories |
Huub Schellekens, Utrecht, the Netherlands
|
|
Biosimilars in regulation: update on regulatory guidelines |
Ashraf Mikhail, Swansea, United Kingdom
|
|
Biosimilars in discussion: question & answer session
|
|
|
|
•
Industry Symposium ORTHO BIOTECH |
Saturday, July 15 2006 – 16.00-17.30 |
|
Confronting the challenges of renal anaemia management: translating knowledge into action |
|
Chair: |
Kai-Uwe Eckardt, Erlangen, Germany |
| |
Iain C. Macdougall, London, United Kingdom |
| |
| Welcome and introduction |
| Iain C. Macdougall, London, United Kingdom |
| |
Immunogenicity of biopharmaceuticals: implications of PRCA for anaemia management |
Kai-Uwe Eckardt, Erlangen, Germany |
| |
How similar is similar? EMEA regulations for assessing biosimilars |
Claudio Ronco, Vicenza, Italy |
| |
| Assessing the immunogenicity profiles of erythropoiesis-stimulating agents: the PRIMIS registry |
| Els Vercammen, High Wycombe, United Kingdom |
| |
| Anaemia management: impact on patients and on CKD |
| Jerome A. Rossert, Paris, France |
| |
| Best practices in anaemia management in CKD patients: where are we now and what is the future |
| Iain C. Macdougall, London, United Kingdom |
| |
| Panel discussion and closing remarks |
| Kai-Uwe Eckardt, Erlangen, Germany |
| |
| |
| |
| •
Industry Symposium SHIRE |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
The Management of Hyperphosphataemia: meeting patient needs with Fosrenol® |
| |
| Chair: John Cunningham, London, United Kingdom |
| |
| What are the real goals in the treatment of hyperphosphataemia? |
| John Cunningham, London, United Kingdom |
| |
| The basic science of Fosrenol |
| Marc De Broe, Antwerp, Belgium |
| |
| Fosrenol in clinical practice: meeting patient need |
| Alastair Hutchison, Manchester, United Kingdom |
| |
| Questions and answers |
| |
| |
| |
| •
Industry Symposium GAMBRO |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Dialysis Treatment of Acute Renal Failure |
| |
| Chair: Claudio Ronco, Vicenza, Italy |
| |
| Why dialysis opinion? |
| Claudio Ronco, Vicenza, Italy |
| |
| Therapy initiation |
| Norbert Lameire, Ghent, Belgium |
| |
| Frequency and duration |
| Kai-Uwe Eckardt, Erlangen, Germany |
| |
| Estimating and achieving adequate dose |
| W. Clark, Indianapolis, USA |
| |
| Which anticoagulation? |
| Ravindra L. Mehta, San Diego, USA |
| |
| Who is responsible? |
| Claudio Ronco, Vicenza, Italy |
| |
| Results from the survey |
| Ingrid Ledebo, Lund, Sweden |
| |
| |
| |
| •
Industry Symposium AMGEN |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Improving clinical outcomes in CKD patients: strategies for earlier and better control |
| |
| Chair: Jorge Cannata-Andía, Oviedo, Spain |
| |
| Welcome and introduction |
| Jorge Cannata-Andía, Oviedo, Spain |
| |
| Maintaining Hb stability: continuous challenges, emerging solutions |
| Eric J. Will, Leeds, United Kingdom |
| |
| Importance of early and sustained control of SHPT |
| Jürgen Floege, Aachen, Germany |
| |
| Summary |
| Jorge Cannata-Andía, Oviedo, Spain |
| |
| |
| |
| •
Industry Symposium GENZYME |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Can we improve outcomes in chronic kidney disease? |
| |
| Chair: David Wheeler, London, United Kingdom |
| |
| What is the evidence for improving outcomes in CKD stage 5 |
| David Goldsmith, London, United Kingdom |
| |
| Impact of phosphate binders on bone histomorphometry; results of a one-year bone biopsy study |
| Anibal Ferreira, Lisbon, Portugal |
| |
Cardiovascular calcification in CKD stage 5 – can we alter progression?
|
| Geoffrey Block, Denver, USA |
| |
| Questions & answers |
| |
| |
| |
| •
Industry Symposium GE HEALTHCARE |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Contrast-induced nephropathy (CIN): incidence, implications and practical strategies for its prevention |
| |
| Chair: Francesco Locatelli, Lecco, Italy |
| |
| Introduction |
| Francesco Locatelli, Lecco, Italy |
| |
| The CIN Consensus Working Panel: rationale, methodology and outcomes |
| Fulvio Stacul, Trieste, Italy |
| |
| The clinical burden of CIN in the at-risk patient |
| James Tumlin, Atlanta, USA |
| |
| Strategies to manage patients at risk for CIN |
| Fulvio Stacul, Trieste, Italy |
| |
| Open discussion |
| |
| |
| |
| • Industry Symposium BELLCO |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Emerging concepts in sepsis |
| |
| Chair: Raymond Vanholder, Ghent, Belgium |
| |
| Metabolic energy failure in sepsis |
| Mervyn Singer, London, United Kingdom |
| |
| The role of adsorption in sepsis: practical and technical aspects |
| Claudio Ronco, Vicenza, Italy |
| |
| Clinical experience with CPFA |
| Marco Formica, Cuneo, Italy |
| |
| |
| |
| •
Industry Symposium LEO |
| Sunday, July 16 2006 – 12.00-13.30 |
| |
| Low Molecular Weight Heparin in Nephrology - An update |
| |
| Chair: P. Joffe, Odense, Denmark |
| |
| LMWHs - are they all the same? |
| S. Alban, Kiel, Germany |
| |
| LMWH in Renal Replacement therapy - update |
| P. Joffe, Odense, Denmark |
| |
| Tinzaparin in renal-compromised and replacement patients |
| W. Lim, Hamilton, Canada |
| |
| |
| |
| •
Industry Symposium SHIRE |
| Sunday, July 16 2006 – 18.30-20.00 |
| |
| Glycomics – from basic science to therapy in anaemia and Fabry disease |
| |
| Chair: |
Andreas Schwarting, Mainz, Germany |
| |
Iain C. Macdougall, London, United Kingdom |
| |
| Chairman's introduction |
| Iain C. Macdougall, London, United Kingdom |
| |
| Glycomics - a new science of clinical importance |
| S. Bekri, Amiens, France |
| |
| Applying human cell line technology to erythropoietin |
| M. Howard, Cambridge, USA |
| |
| Fabry disease and its treatment - a concern for nephrologists |
| F. Barbey, Lausanne, Switzerland |
| |
| Discussion and conclusions |
| Iain C. Macdougall, London, United Kingdom |
| |
| |
| |
| •
Industry Symposium ROCHE |
| Sunday, July 16 2006 – 18.30-20.00 |
| |
| Life after transplantation: are we addressing the real challenges? |
| |
| Chair: Donal O'Donoghue, Manchester, United Kingdom |
| |
| Managing gastrointestinal disturbances post-transplantation: is there a need for a systematic approach? |
| Donal O'Donoghue, Manchester, United Kingdom |
| |
| Can we spare the nephron? Protecting long-term graft function in renal transplant patients |
| Michèle Kessler, Vandoeuvres-les-Nancy, France |
| |
| Death with a functioning graft: protecting our transplant patients from cardiovascular disease and malignancy |
| Yves Vanrenterghem, Leuven, Belgium |
| |
| |
| |
| •
Industry Symposium GENZYME |
| Sunday, July 16 2006 – 18.30-20.00 |
| |
| New insights in metabolic nephropathies |
| |
| Chair: Barry Brenner, Boston, USA |
| |
| Disease progression in metabolic nephropathies |
| Barry Brenner, Boston, USA |
| |
| Successful interventions in metabolic nephropathies |
| Christoph Wanner, Würzburg, Germany |
| |
| Preserving the renal function in Fabry patients |
| S. Waldek, Manchester, United Kingdom |
| |
| |
| |
| •
Industry Symposium TORAY |
| Sunday, July 16 2006 – 18.30-20.00 |
| |
| The multiple aspects of middle - large molecular weight uremic toxins: state of the art |
| |
| Chair: Bruno Perrone, Saintes, France |
| |
| Serendipity and the use of dialysis membranes |
| Bruno Perrone, Saintes, France |
| |
| Clinical significance of protein-adsorbable membrane - Analysis with proteomic technique and long-term clinical effects |
| Ikuo Aoike, Niigata, Japan |
| |
| Removal of middle - large molecular
weight proteins with protein-leaking dialyzers |
| Francesco Galli, Perugia, Italy |
| |
| |
| |
| •
Industry Symposium VIFOR |
| Sunday, July 16 2006 – 18.30-20.00 |
| |
| I.V. Iron in CKD: treat early - support gently |
| |
| Chair: Roland M. Schaefer, Munster, Germany |
| |
| Welcome |
| Roland M. Schaefer, Munster, Germany |
| |
| CKD & CHF: does iron matter? |
| Gabriel Mircescu, Bucharest, Romania |
| |
| Maintenance treatment of anaemia in haemodialysis patients: can iron therapy be standarsized? |
| Rudolf P. Wüthrich, Zurich, Germany |
| |
| Questions & answers |
| |
| Closing remarks |
| Roland M. Schaefer, Munster, Germany |
| |
| |
| |
| •
Industry Symposium ROCHE |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Anaemia management: from targets to reality |
| |
| Chair: |
Francesco Locatelli, Lecco, Italy |
| |
Adrian Covic, Iasi, Romania |
| |
| From targets to reality: where are we today? |
| Kai-Uwe Eckardt, Erlangen, Germany |
| |
| Hb control: current clinical practice |
| Paul Stevens, Canterbury, United Kingdom |
| |
| A vision for better anaemia management: new innovations and developments |
| Iain C. Macdougall, London, United Kingdom |
| |
| Making the targets reality with Continuous Erythropoietin Receptor Activation |
| Steven Fishbane, Mineola, USA |
| |
| Question and answer session |
| |
| |
| |
| •
Industry Symposium BAXTER |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Initiation of dialysis from registry to practice |
| |
| Chair: Rosanna Coppo, Turin, Italy |
| |
| CKD and survival trends in Europe from the ERA-EDTA Registry |
| Kitty Jager, Amsterdam, the Netherlands |
| |
| Access management in HD and PD patients |
| Els Boeschoten, Amsterdam, the Netherlands |
| |
| Offering appropriate therapy choices and personalizing dialysis |
| Joanne Bargman, Toronto, Canada |
| |
| |
| |
| •
Industry Symposium WYETH |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Renal transplantation: clues for improving long-term outcomes |
| |
| Chairs: |
Alan Jardine, Glasgow, United Kingdom |
| |
José Morales, Madrid, Spain |
| |
| Chairmen's introduction |
| Alan Jardine, Glasgow, United Kingdom |
| |
| Why renal function is so important for graft survival |
| José Morales, Madrid, Spain |
| |
| Chronic allograft nephropathy: long-term implications on graft survival |
| Giuseppe Grandaliano, Bari, Italy |
| |
| Post-transplant malignancy: can we reduce the risk? |
| Paul Harden, Oxford, United Kingdom |
| |
| CV risk associated with immunosuppressive therapy |
| Alan Jardine, Glasgow, United Kingdom |
| |
| Panel discussion |
| |
| |
| |
| •
Industry Symposium FRESENIUS MEDICAL CARE |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Online Haemodiafiltration (HDF) – Tomorrow’s treatment standard for optimum patient care |
| |
| Chairs: |
Ziad Massy, Amiens, France |
| |
Bernard Canaud, Montpellier, France |
| |
| From uremic toxins to better dialysis – An update by the EUTox group |
| Raymond Vanholder, Ghent, Belgium |
| |
| Online HDF – Optimising therapy and prolonging survival |
| Bernard Canaud, Montpellier, France |
| |
| HDF - Evolution to the goldstandard |
| Roger Greenwood, London, United Kingdom |
| |
| |
| |
| •
Industry Symposium NABI BIOPHARMACEUTICALS |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Current strategies for the management of hyperphosphatemia in End-Stage Renal Disease |
| |
| Chair: David Goldsmith, London, United Kingdom |
| |
| Introduction / Overview of calcium and phosphate in CKD |
| David Goldsmith, London, United Kingdom |
| |
| Cardiovascular disease in CKD: where does calcium fit in? |
| Peter McCullough, Royal Oak, USA |
| |
| Calcium acetate: a credible, convenient and cost-effective phosphate binder |
| Charles Nolan, San Antonio, USA |
| |
| Preserving bone health without compromising other organ systems: a 21st century challenge for nephrologists |
| Adrian Covic, Iasi, Romania |
| |
| Question and answer session / Panel discussion |
| |
| |
| |
| •
Industry Symposium ABBOTT |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Vitamin D analogs: secondary hyperparathyroidism and beyond |
| |
| Chair: Jürgen Bommer, Heidelberg, Germany |
| |
| CKD and early manifestation of Vitamin D deficiency and secondary hyperparathyroidism |
| Eberhard Ritz, Heidelberg, Germany |
| |
| Vitamin D analogs and the treatment of secondary hyperparathyroidism in CKD stages 3 through 5 |
| Jorge Cannata-Andía, Oviedo, Spain |
| |
| Vitamin D and Mortality: New Theories In Explaining Vitamin D’s Link to Improved Outcomes |
| Ravi Thadhani |
| |
| |
| |
| •
Industry Symposium ASPREVA |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Lupus Nephritis: assessing the evidence, considering the future |
| |
| Chair: Philippe Lesavre, Paris, France |
| |
| Thirty years of cyclophosphamide: assessing the evidence |
| Frédéric Houssiau, Brussels, Belgium |
| |
| Current management of Lupus Nephritis: popular misconceptions |
| David Jayne, Cambridge, United Kingdom |
| |
| Exploring new territory: considering the future |
| Marion Haubitz, Hannover, Germany |
| |
| |
| |
| • Industry Symposium HOSPAL |
| Monday, July 17 2006 – 12.00-13.30 |
| |
| Advanced care of dialysis patients: effective tools for managing cardiovascular episodes |
| |
| Chair: R.M. Lindsay, London, Canada |
| |
| Introduction |
| R.M. Lindsay, London, Canada |
| |
| Hemocontrol as a tool for high blood pressure treatment in hypertensive dialysis patients |
| Antonio Santoro, Bologna, Italy |
| |
| Arrhythmia in the dialysis patient: current understanding and issues to be solved |
| Gerard London, Fleury-Merogis, France |
| |
| Towards hemodialysis without systemic anticoagulation |
| Jacques Chanard, Reims, France |
